UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 285

Sortiert nach

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy

Blood, 2016-07, Vol.128 (2), p.253-264

2016

Link zum Volltext

Verfügbarkeit prüfen

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3322-3327

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Blood, 2012-11, Vol.120 (22), p.4317-4323

2012

Link zum Volltext

Verfügbarkeit prüfen

Epigenetics in Cancer: A Hematological Perspective

PLoS Genetics, 2016-10, Vol.12 (10), p.e1006193-e1006193

2016

Link zum Volltext

Verfügbarkeit prüfen

Emerging treatment options for patients with high-risk myelodysplastic syndrome

Therapeutic Advances in Hematology, 2020-11, Vol.11, p.204062072095500-2040620720955006

2020

Link zum Volltext

Verfügbarkeit prüfen

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

Expert opinion on investigational drugs, 2011-02, Vol.20 (2), p.287-295

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

Journal of hematology and oncology, 2022-10, Vol.15 (1), p.155-6, Article 155

2022

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Blood advances, 2020-07, Vol.4 (13), p.2866-2870

2020

Link zum Volltext

Verfügbarkeit prüfen

Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4747-4753

2009

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases

Frontiers in oncology, 2021-09, Vol.11, p.730503

2021

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer

PloS one, 2015-05, Vol.10 (5), p.e0123768-e0123768

2015

Link zum Volltext

Verfügbarkeit prüfen

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities

Frontiers in immunology, 2018-05, Vol.9, p.977-977

2018

Link zum Volltext

Verfügbarkeit prüfen

Insights into novel emerging epigenetic drugs in myeloid malignancies

Therapeutic Advances in Hematology, 2019, Vol.10, p.2040620719866081-2040620719866081

2019

Link zum Volltext

Verfügbarkeit prüfen

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

British journal of haematology, 2012-06, Vol.157 (6), p.764-766

2012

Link zum Volltext

Verfügbarkeit prüfen

Protein tyrosine kinase 7 has a conserved role in Wnt/β-catenin canonical signalling

EMBO reports, 2011-01, Vol.12 (1), p.43-49

2011

Link zum Volltext

Verfügbarkeit prüfen

Definition of Personalized Medicine and Targeted Therapies: Does Medical Familiarity Matter?

Journal of personalized medicine, 2021-01, Vol.11 (1), p.26

2021

Link zum Volltext

Verfügbarkeit prüfen

P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e27202d1-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW‐ OR INTERMEDIATE‐RISK MYELODYSPLASTIC SYNDROMES

HemaSphere, 2023-08, Vol.7 (S3), p.e811250b-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

Haematologica (Roma), 2013-02, Vol.98 (2), p.e18

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms

Blood advances, 2019-05, Vol.3 (9), p.1540-1545

2019

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Do not lose focus on myeloid biology in the era of COVID-19

Current opinion in hematology, 2021-03, Vol.28 (2), p.71

2021

Link zum Volltext

Verfügbarkeit prüfen

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML‐001 TRIAL

HemaSphere, 2023-08, Vol.7 (S3), p.e930876b-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Oncotarget, 2016-12, Vol.7 (52), p.85937-85947

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 285

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(264)
Mit Volltextzugriff
(252)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(128)
Life Sciences & Biomedicine
(127)
Humans
(124)
Hematology
(102)
Female
(60)
Male
(59)
Aged
(58)
Middle Aged
(58)
Oncology
(58)
Adult
(49)
Myelodysplastic Syndromes - Drug Therapy
(34)
Treatment Outcome
(34)
Leukemia, Myeloid, Acute - Drug Therapy
(33)
Prognosis
(32)
Acute Myeloid Leukemia
(29)
Aged, 80 And Over
(29)
Myelodysplastic Syndromes - Genetics
(24)
Life Sciences
(23)
Leukemia, Myeloid, Acute - Genetics
(22)
Myelodysplastic Syndromes - Mortality
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(112)
Haematologica
(14)
Leukemia & Lymphoma
(14)
Journal Of Clinical Oncology
(13)
Leukemia Research
(12)
British Journal Of Haematology
(11)
Clinical Lymphoma, Myeloma And Leukemia
(10)
American Journal Of Hematology
(8)
Oncotarget
(8)
Blood Advances
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Epigenetics in Cancer: A Hematological Perspective

Emerging treatment options for patients with high-risk myelodysplastic syndrome

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup

Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases

Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities

Insights into novel emerging epigenetic drugs in myeloid malignancies

Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure

Protein tyrosine kinase 7 has a conserved role in Wnt/β-catenin canonical signalling

Definition of Personalized Medicine and Targeted Therapies: Does Medical Familiarity Matter?

P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW‐ OR INTERMEDIATE‐RISK MYELODYSPLASTIC SYNDROMES

Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms

Editorial: Do not lose focus on myeloid biology in the era of COVID-19

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML‐001 TRIAL

P459: DISEASE MONITORING OF NPM1‐MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL‐AZA) TREATMENT (TX): A QUAZAR AML‐001 SUBANALYSIS

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies

Suchergebnisse filtern